Pharmala Biotech Holdings's total inventories for the quarter that ended in Feb. 2026 was $0.28 Mil. Pharmala Biotech Holdings's average total inventories from the quarter that ended in Nov. 2025 to the quarter that ended in Feb. 2026 was $0.27 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Pharmala Biotech Holdings's Net-Net Working Capital per share for the quarter that ended in Feb. 2026 was $-0.00.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Pharmala Biotech Holdings's Days Inventory for the
three
months ended in Feb. 2026 was 1,446.58.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Pharmala Biotech Holdings's Inventory Turnover for the quarter that ended in Feb. 2026 was 0.06.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharmala Biotech Holdings's Inventory-to-Revenue for the quarter that ended in Feb. 2026 was 1.31.
Pharmala Biotech Holdings (OTCPK:MDXXF) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Pharmala Biotech Holdings's Net-Net Working Capital Per Share for the quarter that ended in Feb. 2026 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Pharmala Biotech Holdings's Inventory to Revenue for the quarter that ended in Feb. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Pharmala Biotech Holdings Total Inventories Related Terms
Pharmala Biotech Holdings Total Inventories Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pharmala Biotech Holdings Total Inventories Calculation
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Pharmala Biotech Holdings (MDXXF) has a Total Inventories of $0.28 Mil as of Feb. 2026. The total amount of inventory as recorded on a company's balance sheet. View historical data for Pharmala Biotech Holdings and its competitors.
Is Pharmala Biotech Holdings' Total Inventories too high?
Pharmala Biotech Holdings' current Total Inventories is $0.28 Mil. Overall, Pharmala Biotech Holdings has a GF Score™ of 35/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Pharmala Biotech Holdings' Total Inventories compare to VRTX and REGN?
Pharmala Biotech Holdings' Total Inventories of $0.28 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Biotechnology company?
A good Total Inventories depends on the Biotechnology industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Pharmala Biotech Holdings and its competitors. Pharmala Biotech Holdings's current Total Inventories is $0.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharmala Biotech Holdings stock overvalued right now?
Based on GuruFocus' analysis, Pharmala Biotech Holdings (MDXXF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.15, compared to a current price of $0.11 — trading 28.2% below its estimated fair value. The current Total Inventories is $0.28 Mil. Pharmala Biotech Holdings' overall GF Score™ is 35/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Pharmala Biotech Holdings (MDXXF), the current Total Inventories is $0.28 Mil as of Feb. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pharmala Biotech Holdings (MDXXF) Overvalued in 2026?
Based on GuruFocus' analysis, Pharmala Biotech Holdings stock appears to be undervalued.
The current stock price of $0.11 is trading 28.2% below its estimated GF Value™ of $0.15.
GuruFocus considers Pharmala Biotech Holdings to be Modestly Undervalued.
Key valuation signals for MDXXF:
Total Inventories: $0.28 Mil
GF Value™: $0.15 vs. price of $0.11 (28.2% below fair value)
No single metric tells the full story. See the MDXXF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pharmala Biotech Holdings Inc is a Canadian Biotechnology company focused on the development, manufacture and sales of MDMA and MDXX class molecules in service to the burgeoning clinical research community and growing commercial use cases in select jurisdictions. The company produces its MDMA active pharmaceutical ingredient under the LaNeo brand through Good Manufacturing Practice (GMP) processes, aiming to address shortages for clinical trials investigating treatments for various disorders. It generates revenue from the sale of tablets, raw MDMA and MDXX compounds/formulations, and royalties from licensing of its IP.
35GF Score
Get the complete analysis for MDXXF
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MDXXF has been successfully added to your 
